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ABSTRACT   
 
 
The pulmonary endothelium is a dynamic, metabolically active layer of squamous 
endothelial cells ideally placed to mediate key processes involved in lung 
homeostasis. Many of these are disrupted in the Acute Respiratory Distress 
Syndrome (ARDS), a syndrome with appreciable mortality and no effective 
pharmacotherapy. In this review, we consider the role of the pulmonary endothelium 
as a key modulator and orchestrator of ARDS, highlighting advances in our 
understanding of endothelial pathobiology and their implications for the development 
of endothelial targeted therapeutics including cell-based therapies. We also discuss 
mechanisms to facilitate the translation of preclinical data into effective therapies 
including the application of biomarkers to phenotype ARDS patients with a 
predominance of endothelial injury and emerging biotechnologies that could enhance 
delivery, discovery and testing of lung-endothelial specific therapeutics. 
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INTRODUCTION 
 
The pulmonary vasculature is a homogenous layer of squamous endothelial cells 
lining the entire pulmonary circulation. Having initially been thought of as an inert, 
static structure, the lung endothelium is increasingly recognised as a dynamic, 
metabolically active organ that modulates several key regulatory functions including: 
leukocyte diapedesis, intravascular coagulation, vasomotor tone and solute and fluid 
trafficking via regulation of barrier permeability.  
 
The pulmonary endothelium is distinct from the systemic vascular bed, in that it is 
exposed to the highest oxygen tension, whilst maintaining low-pressure blood flow. 
Coupled with the lung possessing the highest abundance of endothelial cells relative 
to total cell population and its vast surface area, it is ideally placed to interact with 
blood-borne cells and vasoactive mediators to sense mechanical, chemical and 
cellular stimuli. Whilst this allows the endothelium to regulate local (and possibly 
systemic) inflammation, disruption of lung endothelial homeostatic mechanisms 
transforms it from a primarily anti-inflammatory phenotype to an activated pro-
inflammatory phenotype that propagates lung parenchymal inflammation [1].  
Disruption of lung endothelial homeostasis manifests clinically as Acute Respiratory 
Distress Syndrome (ARDS). ARDS is characterised by acute inflammation of the gas 
exchange surface of the lung. Dysregulated inflammation promotes the pulmonary 
accumulation of leukocytes and platelets, whilst activation of pro-coagulant pathways 
and disruption of alveolar capillary membrane barrier function leads to hypoxia, 
hypercapnoea and pulmonary oedema. Thus, ARDS presents clinically with acute 
onset of breathlessness and hypoxaemia in the presence of diffuse pulmonary 
oedema on the chest radiograph, with the majority of patients requiring mechanical 
ventilation. Risk factors for ARDS can be divided into two groups, depending on 
whether injury to the lung is direct such as pneumonia, with predominantly epithelial 
injury, or indirect blood-borne insults, such as severe sepsis, with a predominance of 
endothelial injury (table 1). Although mortality in ARDS has temporally declined, it 
remains between 25 and 35% [2] and there is currently no licensed effective 
pharmacotherapy, highlighting the need for novel therapeutic strategies. 
Contemporary management focuses on treatment of the underlying cause and organ 
support whilst avoiding iatrogenic injury, most notably with low tidal volume and 
pressure mechanical ventilation and a conservative fluid management strategy [3]. 
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Table 1 Indirect and direct ARDS - distinguishing features 
 Indirect ARDS Direct ARDS 
Causes Severe Sepsis 
Trauma 
Blood product transfusion 
(TRALI) 
Pancreatitis 
Cardio-pulmonary bypass 
Burns 
Pneumonia 
Aspiration 
Smoke inhalation 
Pulmonary contusion 
Reperfusion injury 
Clinico-pathological 
Hallmarks 
Neutrophilic alveolitis 
Hyaline membranes 
Microthrombi 
Probable predominance of 
endothelial injury 
Imaging and plasma evidence 
of (non-pulmonary) pathology 
e.g. pancreatitis 
Neutrophilic alveolitis 
Hyaline membranes 
Microthrombi 
Probable predominance of 
alveolar epithelial injury 
Chest imaging evidence (CT) 
of initiating process e.g. lung 
contusion 
Proposed 
Biomarkers 
Angiopoetin-2 
von-Willebrand factor 
Soluble thrombomodulin 
Interleukin-8 
Soluble ICAM-1 
Surfactant protein-D 
Receptor for advanced 
glycation end-products 
Krebs von den Lungen-6 
Club cell 16 
CT: Computed Tomography; ICAM-1: intracellular adhesion molecule 1; TRALI; transfusion associated 
lung injury. 
In this article we focus on our current understanding of the role of the pulmonary 
endothelium in orchestrating and propagating ARDS, and further explore the 
endothelium as an emerging pharmacological target in ARDS. It is important to note 
that the pulmonary endothelium is structurally, morphologically and functionally 
distinct from the systemic vasculature (reviewed in [4 5]). Accordingly, this review will 
address data generated in relevant models of pulmonary endothelial injury, with 
reference to recent specific expert reviews where appropriate. 
 
STRUCTURE AND FUNCTION OF THE PULMONARY ENDOTHELIUM 
 
The pulmonary endothelium forms a single layer of mesenchyme-derived, non-
fenestrated endothelial cells. This serves as a semi-permeable barrier separating the 
pulmonary circulation from the lung interstitium, regulating macromolecule, nutrient, 
leukocyte and fluid transfer.  
 
The integrity of this barrier is determined by homophilic interactions between 
neighbouring endothelial cells via intercellular junctions (tight junctions and adherens 
junctions; reviewed in [6]). These junctions link endothelial cells and are served by 
cytoskeletal microtubules and actin microfilaments to facilitate both maintenance of 
barrier function and modulation of signal transduction in response to the tethering 
and contractile forces exerted on the endothelium during mechanical ventilation [7].  
 
Tight junctions are formed by the fusion of the outer layers of the plasma membranes 
and are comprised of occludins, claudins and junctional adhesion molecules coupled 
to cytoplasmic proteins and linked to the endothelial cell actin cytoskeleton by the 
zona occludens family (ZO). Adherens junctions (AJ) are composed of cadherins, 
primarily vascular endothelial cadherin (VE-cadherin), that bind intracellular catenin 
proteins (including p120-catenin, a VE-cadherin stabilising protein) that in turn bind to 
other protein partners in the actin cytoskeleton. AJ are mediated by calcium 
dependent association of cadherin proteins and regulate the paracellular transport 
(the predominant pathway) of cells and solutes between the blood and the 
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interstitium. Hence AJ, and specifically VE-cadherin, are key regulators of 
paracellular permeability, which determines leukocyte transmigration and oedema 
formation [8] whilst cell membrane scaffolding proteins called caveolins regulate 
trans-endothelial trafficking (transcytosis) of macromolecues including albumin [9 10]. 
Data suggest that transcellular permeability increases may precede and 
subsequently trigger paracellular permeability via Src-mediated phosphorylation of 
caveolin-1 [10].Endothelial cells are tethered to the extra-cellular matrix (ECM) via 
interaction between cell surface integrins and their ECM ligands, which are organised 
in focal adhesion plaques [11]. 
 
A negatively charged extracellular layer of proteoglycans, glycoproteins and 
glycosaminoglycans (GAGs) that line intimal surfaces, the endothelial glycocalyx, 
may act as an additional barrier to large molecules and circulating cells. Data from a 
murine ARDS model suggested that the glycocalyx modulated neutrophil diapedesis 
via heparinase mediated glycocalyx shedding and consequent exposure of neutrophil 
adhesion molecules [12], whilst in vitro human data proposed that the sialic acid 
component of the glycocalyx maintained barrier function via regulation of cell-matrix 
and cell-cell interactions [13]. Despite these and other observations (reviewed in 
[14]), it remains unclear whether and how the glycocalyx contributes to the 
pathogenesis of human ARDS.  
 
The endothelium performs additional regulatory roles in gas exchange, vascular tone 
and coagulation (reviewed in [15]). As an integral component of the alveolar-capillary 
unit, it is structurally and functionally optimised to facilitate perfusion-ventilation 
matching. Hence, lung endothelial cells regulate the synthesis and metabolism of 
vasoactive compounds such as nitric oxide and endothelin-1, potent regulators of 
pulmonary vascular tone. Furthermore, the endothelium also produces both pro- and 
anti-thrombotic substances which act both locally and remotely to regulate 
coagulation. It separates blood borne cellular (e.g. platelets) and humoral (e.g. 
coagulation factors) components of the coagulation cascade from pro-thrombotic 
substances in the lung interstitium and alveolar space.  
 
 
PULMONARY ENDOTHELIAL ACTIVATION IN ARDS 
 
PATHOBIOLOGY  
In health, the lung endothelium adopts a predominantly inhibitory effect on 
inflammation and coagulation. However, upon ‘activation’ by a range of stimuli 
including hypoxia, cytokines (e.g. Tumour Necrosis Factor Alpha (TNF) and 
Interleukin (IL)-1β), chemokines (e.g. Interleukin-8 (IL-8)), thrombin, and bacterial 
endotoxins, including lipopolysaccharide (LPS) and interactions with activated 
inflammatory cells, a shift towards a pro-inflammatory phenotype occurs [1]. Indeed, 
dysregulated endothelial activation and the resultant loss of homeostatic 
mechanisms are aspects of ARDS pathobiology that may distinguish it from self-
limiting, localised insults, for example bacterial pneumonia [1].  
Accordingly, lung endothelial cells are increasingly recognised as orchestrators of the 
inflammatory response. In experimental influenza models, the pulmonary 
endothelium was a key regulator of innate cellular and cytokine responses, if not the 
actual source of cytokine release [16]. In addition, endothelial cells express various 
leukocyte adhesion molecules including intracellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1) and E-selectin [17]. These pro-
inflammatory responses may exhibit calcium dependency; TNF and IL-8 release from 
lung microvascular endothelial cells stimulated with LPS correlated with an increase 
in intracellular calcium [18], whilst cytosolic calcium oscillations induced pro-
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inflammatory gene transcription and endothelial E-selectin expression [19]. Reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) production by activated 
cells saturate local antioxidants and contribute to tissue injury directly via; down-
regulation of VE cadherin [20]; up-regulation of neutrophil adhesion molecule 
expression and release of neutrophil chemotactic factors [21]. 
 
Activated endothelial cells also assume a pro-coagulant phenotype to limit damage 
to lung microvasculature and localise infection. This is characterised by increased 
expression of platelet adhesion molecules, intra-alveolar and intravascular fibrin 
deposition and release of activators of the extrinsic coagulation cascade [22], in 
particular nitric oxide [23]. Moreover, up-regulation and activation of tissue factor and 
loss of the ability to activate protein C and S results in capillary thrombosis and extra-
vascular fibrin deposition, thereby contributing to the increased dead-space fraction 
that correlate with clinical outcomes [24].  
 
CLINICAL AND THERAPEUTIC SIGNIFICANCE  
 
Whilst potentially propagating injury, the expression and release of pro-inflammatory 
molecules has driven research firstly into utilising these molecules as biomarkers of 
ARDS and secondly as putative pharmacological targets. Moreover, there is 
increasing evidence that the alveolar and vascular compartments are biologically 
distinct despite the alveolar capillary membrane disruption seen in ARDS supporting 
the notion that ‘phenotypic signatures’ identifying patients with site-predominant 
injury (endothelial vs epithelial) could be generated. 
Angiopoetin-2 (Ang-2) is an endothelial growth factor produced by endothelial cells 
that regulates vascular permeability, promoting cell death and vascular regression. 
An incremental rise in plasma Ang-2, suggestive of progressive endothelial injury [25] 
predicted mortality in patients with sepsis related ARDS [26]. Similarly, higher 
circulating GAG levels (reflecting the integrity of the glycocalyx) were found in those 
patients with non-pulmonary insults (ie. indirect ARDS patients) although these did 
not predict outcome [27]. In other studies, plasma levels of soluble thrombomodulin 
[28], the circulating form of a transmembrane endothelial glycoprotein with anti-
thrombotic and anti-inflammatory capabilities, and von Willebrand Factor (vWF) [29], 
a glycoprotein produced by endothelial cells, predicted mortality in ARDS. Finally, 
endothelial derived microparticles (EMP), sub-micron vesicles formed during 
membrane blebbing that shuttle proteins, organelles, lipids, and RNA are an 
emerging biomarker of lung endothelial activation (reviewed in [30]), particularly in 
the context of mechanical stretch. Hence, EMP levels were elevated in human 
macrovascular endothelial cells and animals exposed to pathologic mechanical 
stress as well as endotoxin [31 32].  
Using unbiased latent class analysis, a recent study identified two distinct cohorts of 
ARDS patients who differed predominantly in their inflammatory profile, and more 
significantly divergent responses to the application of different ventilator strategies 
[33]. Whilst this study did not differentiate endothelial injury from epithelial injury, it 
suggests that patient endotyping may hold value in predicting response to therapy. 
Coupled with evidence from biomarker studies outlined above, it is becoming 
increasingly plausible that researchers may soon be able to enroll sub-phenotypes of 
ARDS patient with a predominance of endothelial injury to enrich enrollment in trials, 
thus optimizing trial design and potentially outcomes. 
 
The expression of cell surface receptors and adhesion molecules also provides a 
putative platform to apply advances in pulmonary endothelial immunotargeting. 
Coupled with Advanced Drug Delivery systems (ADDs, such as liposomes, 
nanocarriers and host carriers) this methodology may facilitate targeting of specific 
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aspects of lung endothelial injury in ARDS. For example, antioxidants conjugated 
with antibodies to the endothelial determinant PECAM-1 inhibited endothelial 
activation and reduced VCAM-1 expression in murine lung injury [34]. Similarly, 
dexamethasone loaded nanogels targeted to ICAM-1 accumulated in murine LPS-
injured lungs and blocked expression of ICAM-1 and VCAM-1 at 24 hours [35]. In an 
effort to both target the lung endothelium and enhance biologic effect, researchers 
have fused single-chain fragments of PECAM-1 antibodies to recombinant 
thrombomodulin (TM) and endothelial protein C receptor (EPCR). Using this dual-
targeting approach, a 5-fold increase in receptor activation compared to isolated TM 
or EPCR targeting was observed as well as amelioration of lung injury parameters 
[36]. Translation of these methods to clinical use will be challenging, and costs may 
be prohibitive, nonetheless, these novel methods of targeted drug delivery hold 
promise.  
 
 
MECHANISMS OF ENDOTHELIAL BARRIER DISRUPTION AND INJURY IN 
ARDS 
 
Loss of barrier integrity, characterised by the formation of reversible intercellular 
gaps between endothelial cells, is accepted as the ultra-structural basis for the 
increased permeability pulmonary oedema observed in ARDS [37]. A range of 
circulating (TNF, IL-6, LPS), released (reactive oxygen species (ROS), histamine) 
and physical (mechanical stretch) effectors disrupt the endothelial barrier, principally 
by causing aactivation of the actin-myosin contractile apparatus which cause 
dispersion of cortical actin filaments and increased prominence of stress fibres which 
extend throughout the cytoplasm. Actinomyosin contraction of these stress fibers 
increases tension and is proposed to cause cell contraction, pulling cells apart and 
compromising barrier integrity [7]. Contractile machinery is regulated by the 
phosphorylation status of the critical actin binding protein, myosin light chain (MLC) 
on Ser-19 or Ser-19/Thr-18. This is controlled through an interplay of the 
calcium/calmodulin dependent MLC kinase (MLCK, phosphorylation) and Rho 
regulated MLC phosphatase (MLCP, dephosphorylation) [38]. Hence, MLCK in 
particular, plays an essential role in both barrier disruption and restoration in an 
agonist specific manner [39-41] (figure 1).  
Although data specific to the lung endothelium is comparatively limited, regulatory 
small GTPases including RhoA, Rac1, cell division control protein 42 (Cdc42) and 
Rap1 are central intracellular regulators of the actin cytoskeleton and thus barrier 
function.  Broadly, Rho negatively regulates barrier function [42] and Cdc42 and 
Rap1 signaling enhance barrier function [43 44]. RhoA through its regulated 
signalling circuitry, including the serine-threonine Rho kinase (ROCK), induces 
phosphorylation of MLC (via MLCK) as well as inhibition of MLCP, inducing 
cytoskeletal remodelling and barrier permeability [45-47]. Cdc42 directly regulates 
cortical actin organization as well as a host of proteins including cofilin, MLCK and 
neural-Wiscott Aldrich syndrome protein (N-WASP) that affect actin organization and 
cell adhesion to the ECM [44]. Rac1 can either positively or negatively regulate 
barrier function in a stimulus dependent manner [48-50] whilst Rap1, enhances 
barrier function via inhibition of Rho and activation of Cdc42 [51 52] as well as a co-
operative association with VE-cadherin [53].  
Other intracellular mediators include cyclic AMP (cAMP), nuclear factor kappa B 
(NFκ-B) and focal adhesion kinase. An increase in cAMP levels in response to a 
range of mediators reduces vascular leakage through activation of protein kinase A 
(PKA) and the guanine exchange factor, exchange protein activated by cAMP (Epac) 
[54 55]. PKA inhibits RhoA activation and EC contraction [56] and Epac (via Rap1) 
enhances VE-cadherin junctional integrity and actin reorganization [53]. FAK, a non-
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receptor tyrosine kinase regulates turnover of focal adhesion formation by binding to 
focal adhesion proteins as well as enhancing AJ formation [6]; in experimental ARDS 
models (including conditional FAK deletion), decreased FAK expression was 
associated with lung oedema as well as albumin and neutrophil influx [57].   
 
MLC-phosphorylation independent mechanisms of barrier disruption also exist. 
Endothelial cell apoptosis via mediators including TNF [58] and influenza virus [59] 
may contribute. Tyrosine phosphorylation of cytoskeletal proteins and adhesion 
molecules including VE-cadherin, β-catenin and p120 via tyrosine kinases including 
Src [60] may induce disassembly of the catenin-cadherin complex [61 62] whilst 
microtubule disassembly independent of MLCK and Rho has been reported [63 64].  
 
The angiopoietin-Tie2 signalling axis (the endothelial tyrosine kinase Tie2 and its 
circulating ligands angiopoetins 1-4) merits specific mention as a mediator of barrier 
disruption as it represents one of the most extensively studied barrier-regulating 
mechanisms. Ang-1 is constitutively expressed in a range of cell types and mediates 
barrier integrity and endothelial quiescence via steady activation of the Tie2 receptor, 
which is abundantly expressed in endothelium. Ang-2, released from endothelial cells 
in response to a diverse range of mediators [65 66], acts as a functional antagonist of 
Ang-1 at the Tie2 receptor, mediating cytoskeletal rearrangement [25] and junctional 
disruption [67]. Thus, mice heterozygous for Ang-2 were protected from lung injury 
compared to wild type mice in sepsis models [67]. Ang-2 may play additional roles in 
leukocyte endothelial interactions [66]. In the clinic, circulating levels of Ang-2 
correlated with increased pulmonary oedema and mortality in ARDS patients [26] 
and predicted the development of ARDS in critical illness [68] further supporting a 
central role for Ang-2 in the endothelial injury of ARDS. 
 
The role of damage-associated molecular patterns (DAMPs, native molecules 
released after tissue injury) and in particular mitochondrial DNA (mtDNA) production 
in barrier disruption is an emerging area of investigation.  Hence, circulating levels of 
mtDNA are elevated in critical illness. [69] In this context, they are potent inducers of 
the inflammasome via Toll-like receptor-9 (TLR-9) [70], activating leukocyte mediated 
lung injury when injected in vivo [71] and endothelial barrier disruption in vitro [72]. A 
bacterial challenge in isolated mouse lungs induced mtDNA release which was 
associated with endothelial hyper-permeability; this effect was replicated with 
exogenous mtDNA and attenuated by blockade of TLR-9 [73]. Further elucidation of 
mechanisms of mtDNA release and their interplay with ROS as well as intracellular 
signalling pathways are required but this represents an intriguing line of investigation, 
if not a potential therapeutic target. Whilst previously thought to contribute primarily 
to lung epithelial injury and repair [74], pathogen-associated molecular patterns 
(PAMP) signalling via pattern recognition receptors (PRRs) may also contribute to 
lung endothelial barrier dysfunction. Accordingly, influenza virus infection up-
regulated PRR expression (specifically TNF receptor 1) in a range of relevant models 
including human lung autopsy specimens, with resultant endothelial leak and 
apoptosis following exposure to Staphylococcus aureus derived PAMPs in vitro [75].   
 
 
CANDIDATE THERAPIES TO ENHANCE ENDOTHELIAL BARRIER FUNCTION 
 
The endogenous lipid growth factor sphingosine-1-phosphate (S1P) enhances 
barrier function through a series of signalling pathways that maintain cortical actin, 
focal adhesions, and tight junctions (reviewed in [76]). S1P receptors are highly 
expressed on pulmonary endothelial cells. Accordingly, S1P and its analogues 
reduced vascular leakage in small and large animal lung injury models [77 78] as 
 9 
well as dampening the cytokine storm in a murine influenza model [16]. The clinical 
application of S1P and its analogues is currently limited by systemic toxicity, most 
notably immunosuppression prompting the use of FTY720 (an S1P analogue) in 
multiple sclerosis [79]. Moreover, in a murine model, prolonged application of S1P 
agonists worsened vascular leakage and promoted fibrosis [80] whilst the S1P 
pathway has been linked to dysregulated fibrogenesis of idiopathic pulmonary 
fibrosis [81]. Safer analogues with promising, if not superior preclinical data, may 
however be on the horizon [82].  
 
Based on the preclinical and clinical data outlined above, the Tie2 axis represents an 
attractive therapeutic target. A stable variant of Ang-1 protected against systemic 
microvascular dysfunction and restored endothelial barrier function in a murine 
sepsis model, [83] whilst Ang-1 therapy rescued barrier disruption in vitro from ARDS 
plasma high in Ang-2. Recent work has demonstrated that a specific 
pharmacological inhibitor of VE–protein tyrosine phosphatase (VE-PTP) catalytic 
activity, AKB-9778, which activates Tie2 [84], blocked lung neutrophil recruitment in 
LPS challenged mice and stabilized lung endothelial junctions via Rap1 [85]. A novel 
Tie-2 agonist rescued mice from severe influenza up to 3 days after infection [59]. 
Improvements in vascular leak were attributed to Tie-2 mediated attenuation of 
endothelial cell apoptosis as cellular proliferation was unaffected. Notably, 
maintenance of barrier function did not impair leukocyte transmigration. This 
observation supports data from study in the systemic circulation suggesting 
independent regulation of these 2 processes [86 87].   
 
The renin-angiotensin system (RAS) is a complex network orchestrating blood 
pressure, electrolyte and fluid homeostasis that has been implicated in the 
pathogenesis of ARDS. Angiotensin-converting enzyme-2 (ACE2) is a endogenous 
modulator of RAS highly expressed in the lung endothelium and alveolar epithelium 
[88] which diverts potentially injurious Angiotensin II (Ang II) signalling via 
conversion of Ang II to Ang 1–7 and inactivation of angiotensin receptors, thus 
negatively regulating RAS [89]. Studies in knockout mice have demonstrated that 
loss of ACE2 worsened sepsis and acid aspiration induced lung injury. [90] ACE2 is 
reported to be the receptor for the SARS coronavirus induced lung injury [91]. More 
recently, compelling data suggest that ACE2 has a central role in the development 
and progression of the potentially lethal avian influenza viruses H5N1 [92] and 
H797 [93 94]. Gain of function ACE1 polymorphisms are also associated with ARDS 
susceptibility and worse outcome [95]. None of these studies offer clear mechanistic 
insight but ACE2 signaling in the lung is likely to be mediated by alveolar epithelial 
cells [88 96]. A Phase IIa trial of a recombinant ACE2 compound in both direct and 
indirect ARDS patients Clinical Trials.gov ID: NCT01597635 has recently completed 
recruitment and interim results are awaited.  
 
HMG-CoA reductase inhibitors (statins) exert pleomorphic, anti-inflammatory, 
immunomodulatory, and antioxidant effects on endothelial cells to promote 
cytoskeletal rearrangement, decrease oxidative stress and modulate gene 
expression [97 98]. Hence, statins attenuated vascular leak in a range of murine ALI 
models [97 99 100]. Despite promising pre-clinical data, including an in vivo human 
inhaled LPS model [101], these findings were not translated into clinical 
improvements in two recent clinical trials [102 103]. Given the extensive data 
supporting a biological effect on the endothelium, it is intriguing to speculate that 
these trials may have been enriched by the enrolment of specific endotypes of 
indirect ARDS patients to optimize outcomes. 
 
A recent phase I clinical trial of 26 patients demonstrated mortality benefit in ARDS 
(n=37) treated with interferon-beta-1a [104]. The proposed mechanisms of benefit 
were modulation of inflammation (possibly neutrophil endothelial interactions) and 
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endothelial barrier function via CD73 mediated dephosphorylation of adenosine 
monophosphate. Whilst non-randomised, the mortality benefit (24% absolute 
reduction) in this study suggests that targeting the lung endothelium may hold 
promise as a viable therapeutic strategy in ARDS. A randomized controlled trial is 
imminent to confirm these findings. This study was also notable by the generation of 
human (ex vivo) data to support animal data prior to early phase trials, a paradigm 
that should be increasingly adopted. 
 
The pleiotropic effects of the tyrosine kinase inhibitor imatinib, particularly in 
attenuation of vascular permeability induced by a broad range of mediators 
(discussed in [105]) have stimulated study into its efficacy as a barrier enhancing 
agent in ARDS. Despite imatinib’s association with peripheral oedema [106], case 
reports have suggested clinical improvements in idiopathic vascular leak [107] and 
bleomycin induced lung injury [108]. Substantiating these clinical observations, 
imatinib attenuated thrombin and histamine induced barrier dysfunction in vitro [109] 
and pulmonary vascular leak in clinically relevant murine models [105 109]. Given its 
multiple sites of action (Table 2), further mechanistic work is required to progress 
Imatinib as a potential therapy in ARDS. 
 
Other candidate therapies have shown promise, but again mechanistic 
understanding in the pulmonary vasculature is not sufficiently advanced. Atrial 
natriuretic peptide (ANP) protects against lipopolysaccharide (LPS) mediated lung 
microvascular leakage by blocking nuclear factor kappa B (NF-κB) activity [110], 
while concurrently enhancing VE-cadherin localisation to AJ [111]. Recent murine 
data support an additional role for ANP in microtubule stabilisation an emerging 
mechanism in regulation of endothelial cell permeability [112]. Of note, a previous 
small clinical trial demonstrated physiological improvements with an infusion of ANP 
[113]. Adrenomedullin (AM), a ubiquitously expressed peptide hormone that binds 
calcitonin receptor-like receptor (CRC) on lung endothelial cells promoting 
intercellular adherence, improved endothelial barrier function in preclinical ALI and 
VALI models [114-116]. Given the abundance of binding sites on the pulmonary 
endothelium, AM also holds promise as a lung endothelial imaging tool using 
99mTechnetium labelling [117]. Finally, Hepatocyte Growth Factor (HGF) has 
recently been shown to suppress LPS-induced endothelial activation and barrier 
disruption possibly via a guanine nucleotide exchange factor [118 119].  
 
A summary of the mediators and mechanisms of barrier disruption and enhancement 
is outlined in table 2 and figure 2. 
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Table 2 Mediators and mechanisms of barrier disruption and enhancement 
BARRIER DISRUPTION  
Molecule Target                             Mechanisms Refs 
Endothelial 
Glycocalyx 
Unknown 
Loss of endothelial homeostatic mechanisms  
Disruption of cell-cell & cell-matrix interactions 
Increased leukocyte adhesion 
[12 13] 
LPS TLR4 
Intracellular calcium influx via DAG induced 
TRPC6 channel activation 
Reduced FAK expression 
MLCK activation 
NF-κB induced inflammatory cytokine release 
[41 57 
120] 
Mechanical 
stretch 
IL-6R 
RhoA activation 
Expression of contractile proteins 
Cytokine release 
[121-
123] 
mtDNA TLR9 
Intracellular calcium influx 
Cytokine release 
[72] 
ROS 
NADPH 
oxidase 
Intracellular calcium influx & MLCK activation [20 21] 
Thrombin PAR1 
Intracellular calcium influx & activation of MLCK & 
RhoA  
[124 
125] 
TNF TNFR1 
Promotion of NF-κB induced inflammatory 
cytokine release & up-regulation of leukocyte 
ligands eg. ICAM-1 
[17] 
 
BARRIER ENHANCEMENT 
 
Molecule Target                            Mechanisms Refs         
ACE2 n/a 
Negative regulation of RAS via inactivation of 
angiotensin receptors 
Abrogation of Ang II signalling & activity 
[89 90] 
Adrenomedullin 
CLR 
complex 
Attenuation of MLCK phosphorylation 
Activation of protein kinase A,  
Promotes intercellular adherence 
[115 
126] 
Ang1 Tie2 
Adherens junction assembly via Rac1 activation 
Inhibition of NF-κB signalling 
Competitive inhibition of Ang2 mediated barrier 
disruption 
[65] 
ANP NF-κB 
Protects against LPS mediated NF-κB signalling 
Enhanced VE-cadherin localisation to AJ  
[110 
111] 
HGF MET 
Activates Rac-dependent cytoskeletal 
rearrangement 
[118 
119] 
IFNβ1a CD73 
Up regulation of CD73 enhancing adenosine 
activity via adenosine dephosphorylation 
[104 
127] 
Imatinib 
c-Abl 
Arg 
PDGFR 
Augmented Rac1 signalling  
Cytoskeletal rearrangement 
Inhibition of LPS induced NF-κB signalling 
 
[105 
109 
128 
129] 
S1P S1PR1 
Stabilization of adherens junctions via Rac1 
Inhibition of cofilin signalling enhancing tight 
junction formation 
[76 
130] 
Statins 
HMGCoA 
reductase 
Abrogation of VEGF signalling via RhoA inhibition 
& Rac1 activation 
[97 99 
100] 
 
 
ACE2: Angiotensin converting enzyme-2; AJ: Adherens junction; Ang1/2; Angiopoetin 1/2; ANP: Atrial 
natriuretic peptide; Arg: Abl-related gene; CD73: Cluster of differentiation 73; CLR: calcitonin receptor-
like receptor; DAG: Diacyglycerol; FAK: Focal adhesion kinase; HGF: Hepatocyte growth factor; 
HMGCoA: 3-hydroxy-3-methyl-glutanyl-CoA; ICAM-1: Intracellular adhesion molecule; IFN β 1a: 
Interferon-beta 1-alpha; IL-6R: Interleukin-6 receptor; LPS: Lipopolysaccharide; MET: Hepatocyte 
growth factor receptor; MLCK: Myosin light chain kinase; mtDNA: mitochondrial DNA; NADPH: 
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Nictotinamide adenine dinucleotide phosphate; NF-κB: Nuclear factor kappa-B; PAR1: Protease-
activated receptor; PDGFR: platelet-derived growth factor receptor; RhoA: Ras homolog gene family, 
member A; RAS: Renin-angiotensin system; Tie2: Tyrosine kinase receptor-2; TJ: Tight junction; TLR4: 
Toll-like receptor 4; TLR9: Toll-like receptor 9; TNF: Tumour necrosis factor; TNFR1: Tumour necrosis 
factor receptor 1; TRPC6: Transient receptor potential cation channel, member 6; S1P: Sphingosine-1-
phosphate; S1PR1: Sphingosine-1-phosphate receptor 1; VEGF: Vascular endothelial growth factor 
 
INTERACTIONS OF THE LUNG MICROVASCULATURE WITH LEUKOCYTES 
AND PLATELETS 
 
Neutrophils are central to the initiation and propagation of inflammation and injury in 
ARDS and neutrophilic alveolitis is a histological hallmark [131]. Their importance in 
ARDS is highlighted by the observation that a decline in respiratory function is seen 
in neutropenic ARDS patients upon recovery of neutrophil counts [132]. Pathway 
analysis of differential gene expression in sepsis induced ARDS compared to sepsis 
alone identified a preponderance of genes regulating neutrophil homeostasis and 
activation [133], further supporting the notion of the role of neutrophilic inflammation.  
 
Despite extensive data from models of the systemic circulation (e.g. murine 
cremaster vessels and human umbilical vein endothelial cells), our mechanistic 
understanding of the role of the pulmonary endothelium in neutrophil sequestration is 
limited. As a consequence of the unique pulmonary capillary microanatomy, the site 
and mechanisms of neutrophil sequestration are different from the systemic 
microcirculation. For example, owing to space constraints in the alveolar capillary 
bed, neutrophils must change their shape to pass through. Moreover, neutrophil 
rolling on the endothelial surface does not occur [134]. Similarly, neutrophils exhibit 
selectin and CD11b/CD18 independent sequestration in pulmonary capillaries [135 
136]. A role for the endothelial glycocalyx in modulation of neutrophil adhesion 
molecule expression (ICAM-1) has been proposed [12], however, precise 
identification of the cognate receptors for neutrophils on lung endothelium remains 
elusive and further study in refined animal models and novel human models is an 
urgent unmet need.  
 
Clarification of the role of neutrophil migration in barrier disruption is also required. 
Activated neutrophils exert negative effects on barrier permeability via secretion of 
various products such as TNF, complement component 5a (C5a) and arachidonic 
acid but it remains unclear whether neutrophil migration through the endothelium is 
damaging per se. As outlined above, recent data support the concept that neutrophil 
migration and endothelial barrier disruption may be independently regulated [59 86 
87]. 
 
Recent work has focused on the role of the transient receptor potential channels 
(TRP), specifically TRP vanilloid 4 (TRPV4) receptor, particularly as it is expressed 
on both neutrophils and the pulmonary endothelium, and specific inhibitors are 
available [137]. TRPV4 signaling has been implicated in endothelial dysfunction 
secondary to mechanical [138] and hydrostatic [139] stress possibly via calcium 
influx [137 140]. Deletion of TRPV4 attenuated both endothelial barrier leak and 
neutrophil activation in a murine acid injury model [137]. Further, chimeric mouse 
models demonstrated that attenuation of lung injury was contingent on endothelial 
TRPV4 as opposed to leukocyte TRPV4 although deletion of TRPV on neutrophils 
did abrogate injury in isolated perfused mouse lungs [137].  
 
The concept that the lung endothelium may play a role in host defense by facilitating 
the de-priming of neutrophils, and hence providing protection from neutrophil-
mediated remote organ injury, has been proposed. Data from an in vivo human 
model demonstrated that the healthy lung microvasculature retained primed cells, 
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and subsequently facilitated their de-priming and release (into the systemic 
circulation) in an un-primed quiescent state [141]. It is conceivable that failure of this 
mechanism, for example as a consequence of endothelial injury in ARDS, may result 
in high circulating levels of primed neutrophils, which correlates with the severity of 
lung injury [142] and which may mediate multi-organ dysfunction. Manipulation of this 
de-priming mechanism may offer a novel therapeutic approach.  
 
Whilst platelets play a role in a range of pathobiological processes in ARDS 
(reviewed in [143]), our understanding of platelet endothelial interactions is under-
developed and extrapolated from work on the systemic vasculature. In murine ARDS, 
platelets induced ICAM-1 expression on endothelial cells, propagating neutrophil 
extravasation [144]. Experimental lung injury models have also demonstrated that 
platelets induce endothelial activation as evidenced by increased expression of vWF, 
P-selectin and tissue factor, such that platelet depletion and blockade of platelet 
binding ameliorated injury [145 146]. Platelets also modulate endothelial barrier 
permeability through expression of a range of factors, including S1P (reviewed in 
[147]). Of note, however, in murine pneumonia, thrombocytopenia enhanced lung 
inflammation and endothelial cell activation suggesting that platelet depletion 
strategies may be detrimental [148]. The interplay between neutrophil extracellular 
traps (NETs) and platelets is an emerging narrative in lung injury secondary to blood 
transfusion [149] and following lung transplantation [150]. Platelet-endothelial 
interaction may also play a role in regulating alveologenesis (see below, [151]) and 
hence lung repair after injury.  
 
MODULATION OF THE COAGULATION CASCADE 
 
Activated coagulation and depressed fibrinolysis coupled with low circulating levels of 
endogenous anticoagulants contribute to the pathological and physiological features 
of ARDS. Moreover, it is becoming increasingly apparent that inflammation and 
coagulation in ARDS are intimately linked [152]. Modulation of these effects has thus 
been an attractive therapeutic target.  
 
The protein C pathway, in particular, has been the focus of extensive research, at 
least in the systemic circulation (reviewed in [153]). Activated Protein C (APC) is 
generated from EPCR-bound protein C by thrombomodulin-bound thrombin. EPCR 
are expressed on both pulmonary artery and lung microvascular endothelial cells 
[154]. In addition to its anticoagulant activity, APC manifests a myriad of 
cytoprotective effects, including anti-apoptotic and anti-inflammatory effects through 
dissociation of APC from EPCR and activation of protease-activated receptor (PAR)-
1 (and to a lesser extent PAR-3) biased signalling [153 155]. In the lung 
macrovascular endothelium, APC enhanced barrier function in a context specific 
fashion via S1P and RAC1-dependent mechanisms [130]. 
 
Despite extensive preclinical data, recombinant APC demonstrated no clinical 
efficacy in ARDS patients [156] and no reduction in barrier leak was demonstrated 
with recombinant APC therapy, [157] despite attenuation of the coagulopathy [158]. 
A multicentre trial of modified (catalytic site irreversibly blocked) recombinant Factor 
VIIa [159], similarly, showed no benefit. Thus, we have yet to fully harness the 
abilities of anticoagulants to modulate cell signalling, inflammation and barrier 
function, in particular via PAR signalling [130 153]. These negative trial data may 
temper enthusiasm for on-going research in this area. Nonetheless, PAR-1 
antagonism has recently shown beneficial effects on neutrophil migration, cytokine 
release and barrier disruption in a murine pneumonia model [160] suggesting that 
alternative targets in the pathway may hold therapeutic promise. 
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THE LUNG ENDOTHELIUM AND REPAIR IN ARDS 
 
The observation that over half of ARDS patients survive [161], suggests that the lung 
microvascular endothelium and epithelium have a significant capacity for repair and 
regeneration. The process of repair following ARDS involves both alveolar and 
endothelial cell reconstitution with restoration of barrier function facilitating removal of 
alveolar oedema and inflammatory debris. A comprehensive discussion of 
endothelial repair is beyond the scope of this article and readers are referred to 
recent expert reviews [162 163] 
 
In addition to circulating progenitor cells, local populations of endothelial progenitor 
cells (EPC) have been identified in the pulmonary microvascular endothelium [164] 
and levels of EPCs are elevated in ARDS patients [165 166]. Retrospective analysis 
of lung tissue from male-to-female haematopoietic stem cell transplant patients 
provides direct evidence of integration of male endothelial progenitor cells into 
female recipient pulmonary endothelium confirming the role of EPC [167]. However, 
the field of circulating EPC remains controversial; their origin and function as well as 
their ability to effect repair under the hostile environment of clinical ARDS remains 
uncertain. Moreover, the cell most commonly studied, (identified by Asahara in 1997 
[168]) is now recognised as a monocyte with angiogenic features and not a true 
endothelial progenitor [169]. Furthermore, it has been demonstrated that the majority 
of endothelial repair, at least after endotoxin-induced lung injury, was affected by 
tissue-resident progenitor cells, not circulating EPCs [170]. Any therapeutic role of 
cell-based therapies may be anti-inflammatory, via secretion of paracrine factors, as 
opposed to mediating endothelial repair per se. 
 
Alternatively, endothelial cells may modulate neo-alveolarisation via cross talk with 
their local niche. Hence, in murine pneumonectomy models platelet-endothelial 
interaction via stromal-cell derived factor-1 [151] and lung endothelial VEGF 
signalling (via the production of matrix metalloproteinase 14) [171] induced 
alveologenesis. Similarly, lung endothelial cells were required to support alveolar 
stem cell differentiation in vitro and lung regeneration in vivo; this mechanism was 
thrombospondin-1 (an endogenous inhibitor of angiogenesis) dependent [172].  
 
These data provide compelling evidence that the pulmonary endothelium participates 
in the resolution of ARDS. Whether manipulation of these endothelial niches or the 
administration and mobilisation of EPC populations is a feasible goal in ARDS 
requires further study. Further definition of the molecular pathways that regulate the 
cross talk between endothelial cells and the reparative niche, particularly in the 
context of relevant ARDS models will be invaluable. Whilst primarily directed towards 
resolution of alveolar epithelial inflammation and injury, data from a clinical trial of 
mesenchymal stem cells [173] (ClinicalTrials.gov: NCT02097641) will hopefully 
provide additional insights, particularly regarding the effects of anti-inflammatory 
strategies on endothelial barrier function and a potential interplay with endothelial 
cells. 
 
 
FUTURE DIRECTIONS 
 
The identification and validation of robust biomarkers to phenotype ARDS patients to 
either identify them as having a predominance of endothelial injury or to predict 
response to treatment would appear an integral component influencing the success 
of future trials of novel endothelial therapeutics in ARDS. The application of ‘omics’ 
technologies such as metabolomics (reviewed in [174]) will hopefully advance this 
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field in the coming years facilitating personalised therapies within the next decade. 
Biomarker exploration will ideally also result in the identification of novel drug-able 
targets. Building on the work by Calfee and others [27 28 33 175], enrichment of 
patient enrolment into focussed clinical trials of novel endothelial-specific 
therapeutics using established biomarkers would appear to be a reasonable strategy 
to optimise patient outcomes. 
 
Further, it is imperative that the heterogeneity between systemic and pulmonary 
vascular endothelium and between animals and humans is increasingly recognised. 
Developing better techniques to interrogate neutrophil-endothelial interactions in the 
lung would seem paramount; the continued development of live imaging in 
transgenic mice using fluorescent probes to label specific cell types [176] and 
increased application of isolated perfused lung models [177] as well as human ex 
vivo and in vivo models represent mechanisms to maximise the translation of 
preclinical data into effective therapeutics. It remains to be seen whether so called 
‘lungs on a chip’ [178] which combine biomimetic systems containing microfluidic 
channels lined by living human cells, will develop into tractable model for lung biology 
per se or specifically ARDS pathobiology. An IL-2 induced injury model recapitulated 
salient features of in vivo ARDS, which were attenuated by a novel TRPV4 
antagonist [179]. This technology has the potential to complement (if not replace) 
current ARDS research platforms, facilitating interrogation of hitherto under-
developed aspects of lung endothelial biology and pharmacology in a co-culture 
platform with biologically relevant cell types (alveolar epithelial cells, lung 
microvascular endothelial cells and leukocytes or platelets) exposed to 
physiologically relevant mechanical forces via a stretchable porous membrane [180]. 
The applications of 3D bioprinting for the study of lung biology [181] similarly 
represents an enticing, if yet unrealized prospect. Development of such innovative, 
humanized models coupled with the refinement of existing models will be central to 
the identification and testing of emerging therapeutics. 
 
 
CONCLUSIONS  
 
The pulmonary endothelium is increasingly seen as pivotal in both the progression 
and the resolution of ARDS and is therefore primed as a therapeutic target. Our 
understanding of endothelial biology, notably neutrophil endothelial interactions in the 
lung vasculature, is a limitation to potential progress. Despite this, enhancement of 
endothelial barrier function, in particular, shows promise in preclinical models of 
ARDS and relevant late phase human trials are imminent. Novel imaging techniques 
and innovative in vitro research platforms may facilitate translation of promising 
animal data into efficacious endothelial specific therapies. Despite enthusiasm for 
their introduction, the use of cell-based therapies requires further characterisation of 
their phenotype, efficacy and safety. In the interim, the application of emerging 
technologies will assist the search for robust biomarkers of endothelial injury, which 
will inevitably enhance enrolment into future clinical trials of novel lung endothelial 
targeted agents.  
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FIGURE CAPTIONS 
 
Figure 1: Mechanisms of pulmonary endothelial barrier disruption and enhancement 
Barrier disruption results from actin-myosin interaction after MLC-phosphorylation, which is regulated by 
myosin light chain kinase (MLCK) and myosin light chain phosphatase (MLCP). Activation of the actin 
myosin contractile apparatus disperses cortical actin and increases actin stress fibre formation, resulting 
in cell contraction and tensional force applied to AJ proteins. RhoA acts via effector protein Rho-
associated kinase (ROCK) to activate MLCK and inhibit MLCP. RhoA activity is inhibited by the 
GTPases Rap1 and Rac1 as well as cyclic AMP induced protein kinase A (PKA) activation. MLCK 
activation is modulated by Ca
2+
which enters the cytosol from endoplasmic reticulum (ER) or 
extracellular space. Phosphorylation of specific tyrosine residues of cytoskeletal proteins and adhesion 
molecules including VE-cadherin as well as microtubule disassembly are MLCK independent 
mechanisms of barrier disruption; Src mediated VE-cadherin phosphorylation leads to VE-cadherin 
internalisation. Nuclear factor kappa B (NFκ-B)
 
activation promotes a pro-inflammatory state resulting 
degradation of the endothelial glycocalyx, which may expose neutrophil ligands. Cyclic AMP (cAMP) 
levels increase in response to a range of mediators to induce activation of protein kinase A (which 
inhibits RhoA) as well as the guanine exchange factor, exchange protein activated by cAMP (Epac). 
Epac (via Rap1) enhances VE-cadherin junctional integrity and actin reorganization. Rap1 enhances 
barrier function via inhibition of Rho and activation of Cdc42 as well as a co-operative association with 
VE-cadherin. Cdc42 directly regulates cortical actin organization and proteins including MLCK and 
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neural-Wiscott Aldrich syndrome protein (N-WASP) that mediate cortical actin formation via interaction 
with focal adhesion kinase (FAK) and actin related protein (ARP) thus strengthening AJ and TJ 
formation as well as cell adhesion to the ECM.  FAK also signals via effector molecules to inhibit RhoA 
and activate Rac1.  
 
Figure 2: Mediators of pulmonary endothelial barrier function 
Thrombin acts via protease activated receptor 1 (PAR1) to induce multiple barrier disruptive 
mechanisms including calcium influx, via transient receptor potential ion channels (TRP), adherens 
junction (AJ) protein phosphorylation via the tyrosine kinase Src and RhoA activation. 
Lipopolysaccharide (LPS), via activation of toll-like receptor 4 (TLR4), increases intracellular calcium 
and activates myosin light chain kinase (MLCK) as well as induction of nuclear factor kappa B (NF-κB) 
signalling, promoting inflammatory cytokine production and neutrophil ligand expression. Mitochondrial 
DNA (mtDNA) acts via toll-like receptor 9 (TLR9) to increase intracellular calcium, activate MLCK and 
promote actin stress fibre formation. Cyclic mechanical stretch (CMS), via interleukin 6 receptor (IL6R) 
disrupts barrier function via Rho-independent mechanisms (circulating IL-6) and Rho-dependent 
mechanisms. Tumour necrosis factor alpha (TNF), via tumour necrosis factor alpha receptor 1 (TNFR1) 
activates NF-κB. An additional mechanism of TNF induced barrier disruption includes tyrosine 
phosphorylation of VE cadherin. Barrier protective mediators sphingosine-1-phosphate (S1P) activates 
sphingosine-1-phosphate receptor 1 (S1P1) to promote MLC phosphorylation and adherens junction 
assembly via Rac1. S1P signalling may have additional immunomodulatory effects in influenza infection. 
Hepatocyte growth factor (HGF), via HGF receptor tyrosine kinase (MET) activates Rac1 activity via the 
adaptor protein IQGAP1. Angiopoetin-1 (Ang1) competes with the functional antagonist Angiopoetin-2 
(Ang2) at the tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2) receptor to 
promote adherens junction assembly and cortical actin formation through Rac1 and inhibition of NF-κB 
signalling. Atrial natriuretic peptide (ANP) also mitigates pro-inflammatory NF-κB signalling and RhoA 
activity. HMG-CoA reductase inhibitors (statins) inhibit RhoA activity. Angiotensin converting enzyme 2 
(ACE2) acts via angiotensin 2 type 1 receptor (AT1R) to inhibit the barrier disruptive effects of 
Angiotensin 2 signalling and renin-angiotensin system activation. Adrenomedullin (AM) acts via 
calcitonin receptor-like receptor (CLR) to activate cyclic adenosine monophosphate (cAMP) signalling, 
mediating barrier enhancement via protein kinase A (PKA) induced RhoA inhibition and endothelial cell 
contraction as well as Rap1 mediated exchange protein activated by cAMP (Epac) activation. 
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